CG Oncology, Inc.

CG Oncology, Inc. (CGON) priced its initial public offering on Jan 25, 2024 at $19.00 per share, above its $16.00–$18.00 range, raising $380M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.21B. Morgan Stanley was lead-left underwriter, joined by Goldman Sachs and Cantor. Latham & Watkins advised the company and Cooley advised the underwriters.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company developing cretostimogene, a bladder-sparing therapy candidate for bladder cancer. Its lead trial is a Phase 3 study in patients with high-risk non-muscle invasive bladder cancer unresponsive to BCG therapy.

Status

IPO

Ticker

CGON

Exchange

Nasdaq Global Select

Priced

Jan 25, 2024

IPO price

$19.00

Price range

$16.00–$18.00

Raised

$380M

Market cap at IPO price

$1.21B

First filed

Jan 2, 2024

Underwriters

Morgan Stanley, Goldman Sachs and Cantor

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.